BIO.B (Bio-Rad Laboratories) Short Percentage of Float

View and export this data going back to 1999. Start your Free Trial

What is Bio-Rad Laboratories Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Bio-Rad Laboratories's Short Percentage of Float

For the Medical Devices subindustry, Bio-Rad Laboratories's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Rad Laboratories's Short Percentage of Float Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Short Percentage of Float falls into.

Save Embed

;

Save Embed

;

Bio-Rad Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio-Rad Laboratories Inc (NYSE:BIO.B) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

BIO:USA BUWA:Germany

Address

1000 Alfred Nobel Drive, Hercules, CA, USA, 94547

Website

https://www.bio-rad.com

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.